Company intelligence / Profile preview
Takata Pharmaceutical
Saitama, Saitama, Japan
- Ownership
- Private
- Employees
- ~790
- Development stage
- Other
01
Overview
Takata Pharmaceutical is a generics-focused pharmaceutical company with approved drugs in Japan, including products for infectious, metabolic, nervous, immune diseases, and oncology. Notably, it is assuming marketing authorization for Elplat (oxaliplatin) for use in gastric and small intestine cancers in Japan.[7][8]
- Therapeutic areas
- ImmunologyEndocrinologyInfectious DiseasesGastroenterologyOncologyNeurology
- Modalities
- Small moleculeHerbal medicineEnzymeChemical drugs
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
KYOSOMIRAI PHARMASANWA KAGAKU KENKYUSHONippon KayakuMaruhoMeiji Seika PharmaYakult HonshaDebiopharm
Beyond the preview
Go deeper on Takata Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Takata Pharmaceutical.